Small Molecules
27 March 2013
Neurocrine Biosciences Announces the Start of Phase IIb Study of Elagolix in Uterine Fibroids26 March 2013
Catabasis Initiates Phase 1 Trial of CAT-2003 for Treatment of Severe Hypertriglyceridemia26 March 2013
Trius Announces Positive Results From ESTABLISH 2 Study of Tedizolid in Severe Skin Infections26 March 2013
BioCryst Announces Initiation of a Phase 1 Clinical Trial of BCX4161 for the Treatment of Hereditary Angioedema26 March 2013
United Therapeutics Announces Receipt Of Second Complete Response Letter For Oral Treprostinil NDA24 March 2013
ARIAD Announces That Iclusig (Ponatinib) Receives Positive CHMP Opinion for Approval in the European Union21 March 2013
FDA Approves Dotarem (gadoterate meglumine), first macrocyclic and ionic gadolinium-based contrast agent in USA21 March 2013
Orion Corporation Presented Promising Phase II Data for New Parkinson’s Disease Drug at AAN Annual Meeting21 March 2013
Orion Corporation Presented Promising Phase II Data for New Alzheimer’s Disease Drug at AAN Annual Meeting21 March 2013
Cytokinetics Announces Presentation of Phase IIA Clinical Trial Data of Tirasemtiv in Patients with Myasthenia GravisNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports